The 4F2 antigen heavy chain induces uptake of neutral and dibasic amino acids in Xenopus oocytes.
The 4F2 cell surface antigen is a disulfide-linked heterodimer induced during the process of cellular activation and expressed widely in mammalian tissues (Parmacek, M. S., Karpinski, B. A., Gottesdiener, K. M., Thompson, C. B., and Leiden, J. M. (1989) Nucleic Acids Res. 17, 1915-1931). The human heavy chain component, a type II membrane glycoprotein, has 29% identity to the amino acid transport-related protein encoded by the recently cloned rat D2 cDNA. We have demonstrated that Xenopus oocytes injected with in vitro transcribed cRNA from D2 take up cystine and dibasic and neutral amino acids (Wells, R. G., and Hediger, M. A. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5596-5600). In the present study, we examine the role of the human 4F2 heavy chain in amino acid transport. In vitro transcribed 4F2 cRNA was injected into Xenopus oocytes which were assayed for the uptake of radiolabeled amino acids. Our results show that cRNA from 4F2 stimulates the uptake of dibasic and neutral amino acids into oocytes at levels up to 3-fold higher than for water-injected control oocytes. There is no demonstrable uptake of cystine. Uptake is saturable, with characteristics of high affinity transport, and inhibition data suggest that uptake occurs via a single transporter. Dibasic amino acids are taken up by both 4F2 and D2 cRNA-injected oocytes in a sodium-independent manner. In contrast, 4F2-induced but not D2-induced neutral amino acid uptake has a significant component of sodium dependence. Likewise, neutral amino acids in excess inhibit the 4F2-induced uptake of radiolabeled arginine but not leucine in a sodium-dependent manner. The 4F2-induced uptake we observe most likely represents the activity of a single transport system with some characteristics of systems y+, b0,+, and B0,+. We suggest that 4F2 and D2 represent a new family of proteins which induce amino acid transport with distinct characteristics, possibly functioning as transport activators or regulators.
Wells
R G
RG
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Lee
W S
WS
Kanai
Y
Y
Leiden
J M
JM
Hediger
M A
MA
D000596:Amino Acids / Q000378:metabolism* / Q000494:pharmacology; D000599:Amino Acids, Diamino / Q000378:metabolism*; D000818:Animals; D000954:Antigens, Surface / Q000235:genetics / Q000378:metabolism*; D001120:Arginine / Q000378:metabolism; D001692:Biological Transport / Q000187:drug effects; D004247:DNA / Q000235:genetics; D027261:Fusion Regulatory Protein-1; D005822:Genetic Vectors; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D007930:Leucine / Q000378:metabolism; D046911:Macromolecular Substances; D008715:Methionine / Q000378:metabolism; D009865:Oocytes / Q000378:metabolism*; D011994:Recombinant Proteins / Q000378:metabolism; D014158:Transcription, Genetic; D014981:Xenopus
D000596:Amino Acids; D000599:Amino Acids, Diamino; D000954:Antigens, Surface; D027261:Fusion Regulatory Protein-1; D046911:Macromolecular Substances; D011994:Recombinant Proteins; D004247:DNA; D001120:Arginine; D008715:Methionine; D007930:Leucine